[1] |
|
[2] |
|
[3] |
谢宇,于亚敏,佘瑞芳,等. 我国分级诊疗发展历程及政策演变研究[J]. 中国医院管理,2017,37(3):24-27.
|
[4] |
|
[5] |
|
[6] |
|
[7] |
张作记. 行为医学量表手册[M]. 中华医学电子音像出版社,2005:157-160.
|
[8] |
|
[9] |
|
[10] |
|
[11] |
LICHTMAN J H, BIGGER J T, BLUMENTHAL J A,et al.Depression and coronary heart disease:recommendations for screening,referral,and treatment:a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing,Council on Clinical Cardiology,Council on Epidemiology and Prevention,and Interdisciplinary Council on Quality of Care and Outcomes Research:endorsed by the American Psychiatric Association[J]. Circulation, 2008, 118(17):1768-1775. DOI: 10.1161/CIRCULATIONAHA.108.190769.
|
[12] |
|
[13] |
|
[14] |
GLASSMAN A H, O'CONNOR C M, CALIFF R M,et al. Sertraline treatment of major depression in patients with acute MI or unstable angina[J]. JAMA, 2002, 288(6):701-709. DOI: 10.1001/jama.288.6.701.
|
[15] |
LESPÉRANCE F, FRASURE-SMITH N, KOSZYCKI D,et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease:the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy(CREATE)trial[J]. JAMA, 2007, 297(4):367-379. DOI: 10.1001/jama.297.4.367.
|
[16] |
BLUMENTHAL J A, SMITH P J, JIANG W,et al. Effect of exercise,escitalopram,or placebo on anxiety in patients with coronary heart disease:the understanding the benefits of exercise and escitalopram in anxious patients with coronary heart disease(UNWIND)randomized clinical trial[J]. JAMA Psychiatry, 2021, 78(11):1270-1278. DOI: 10.1001/jamapsychiatry.2021.2236.
|
[17] |
BLUMENTHAL J A, SMITH P J, JIANG W,et al. Longer term benefits of exercise and escitalopram in the treatment of anxiety in patients with coronary heart disease:six month follow-up of the UNWIND randomized clinical trial[J]. Am Heart J, 2022, 251:91-100. DOI: 10.1016/j.ahj.2022.05.014.
|
[18] |
KIM J M, STEWART R, LEE Y S,et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome:a randomized clinical trial[J]. JAMA, 2018, 320(4):350-358. DOI: 10.1001/jama.2018.9422.
|
[19] |
|
[20] |
STRIK J J, HONIG A, LOUSBERG R,et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction:findings from a double-blind,placebo-controlled trial[J]. Psychosom Med, 2000, 62(6):783-789. DOI: 10.1097/00006842-200011000-00007.
|
[21] |
TIAN X Q, WANG Q, GUO R,et al. Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction[J]. Neuropsychiatr Dis Treat, 2016, 12:2333-2341. DOI: 10.2147/NDT.S109880.
|
[22] |
中国医师协会全科医师分会双心学组,心血管疾病合并失眠诊疗中国专家共识组. 心血管疾病合并失眠诊疗中国专家共识[J]. 中华内科杂志,2017,56(4):310-315.
|
[23] |
|
[24] |
MEDVEDEV V E. Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease:results of the national multicenter observational study PULSE[J]. Neuropsychiatr Dis Treat, 2017, 13:1141-1151. DOI: 10.2147/NDT.S129793.
|
[25] |
|
[26] |
|
[27] |
HO J M, GOMES T, STRAUS S E,et al. Adverse cardiac events in older patients receiving venlafaxine:a population-based study[J]. J Clin Psychiatry, 2014, 75(6):e552-558. DOI: 10.4088/JCP.13m08508.
|
[28] |
BEHLKE L M, LENZE E J, CARNEY R M. The cardiovascular effects of newer antidepressants in older adults and those with or At high risk for cardiovascular diseases[J]. CNS Drugs, 2020, 34(11):1133-1147. DOI: 10.1007/s40263-020-00763-z.
|
[29] |
|
[30] |
HONIG A, KUYPER A M G, SCHENE A H,et al. Treatment of post-myocardial infarction depressive disorder:a randomized,placebo-controlled trial with mirtazapine[J]. Psychosom Med, 2007, 69(7):606-613. DOI: 10.1097/PSY.0b013e31814b260d.
|
[31] |
SWEDA R, SIONTIS G C M, NIKOLAKOPOULOU A,et al. Antidepressant treatment in patients following acute coronary syndromes:a systematic review and Bayesian meta-analysis[J]. ESC Heart Fail, 2020, 7(6):3610-3620. DOI: 10.1002/ehf2.12861.
|
[32] |
|
[33] |
|
[34] |
|
[35] |
ZHOU H F, ZHAO Y, PENG W H,et al. Efficacy and safety of Wuling capsule for insomnia disorder:a systematic review and meta-analysis of randomized controlled trials[J]. Sleep Med, 2022, 93:1-14. DOI: 10.1016/j.sleep.2022.03.014.
|
[36] |
|
[37] |
WANG C L, HUAN N, WANG P L,et al. Guanxin Danshen dripping pills improve quality of life and cardiovascular prognoses of CHD patients after PCI with anxiety or depression(GLAD study):a randomized double-blind placebo-controlled study[J]. Chin J Integr Med, 2023, 29(3):195-204. DOI: 10.1007/s11655-022-3688-3.
|
[38] |
|
[39] |
|
[40] |
CHEN M T, ZHONG G F, MEN L,et al. Effectiveness and safety of Xinkeshu on coronary artery disease patients combined with anxiety and depression symptoms after percutaneous coronary intervention:a protocol for systematic review and meta-analysis[J]. Medicine, 2021, 100(46):e27912. DOI: 10.1097/MD.0000000000027912.
|
[41] |
|
[42] |
|
[43] |
|
[44] |
|